Buy & Sell Intuit Inc. (INTU) – Intuit Inc. Price Today
Aura AI Summary
Key Stats
- $87.52BMarket Cap
- TechnologySector
- -36.18%3M Drawdown
- $85.97BEnterprise Value
- 1.5%Dividend Yield
- 67 daysTypical Hold Time
Intuit Inc. (INTU) is currently valued at a market capitalization of $87.52B, with an enterprise value of $85.97B. Over the past 52 weeks, Intuit Inc. has traded between a low of $307.07 and a high of $807.39, highlighting its annual price range. Over the past three months, Intuit Inc. has recorded a drawdown of -36.18%, reflecting recent price volatility. Intuit Inc. offers a dividend yield of 1.5%, with the most recent dividend of $1.20 paid on 09 Apr 26. On average, investors hold Intuit Inc. for approximately 67 days, indicating typical investor behavior on the platform.
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Most Recent News
Hansa Biopharma to present positive 12-month Phase 3 kidney transplant trial results at American Transplant Congress.
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...

TruBridge faces class action over financial errors and late report filing, shares drop 10.5%.
TruBridge, Inc. disclosed errors in its previously issued financial statements for 2023 and 2024, leading to a late filing of its 2025 annual report. The errors involve revenue recognition, contract costs, stock-based compensation, and capitalized so...

Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop
Disc Medicine, Inc. faced a 22% stock price drop after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. The Rosen Law Firm is investigating potential securities ...
